QMSMEDI NSE filing

QMS Medical Allied Services Ltd. Unveils Investor Presentation for Q2 & H1 FY27

The RealCase readHigh impact Positive

QMS Medical Allied Services Ltd. released its Q2 & H1 FY27 investor presentation. A composite scheme of arrangement approved on September 25, 2026, will demerge services businesses into a separate entity, merging PSP businesses into Saarathi Healthcare. The company targets ₹180 crore revenue for FY27 and is acquiring BeamOptics Scientific. Q2 FY27 revenue was ₹52.5 crore (up 18% YoY), and H1 FY27 revenue reached ₹109.4 crore (up 20% YoY).

Why it matters

The significant strategic moves, including a merger, demerger, and acquisition, along with revenue growth, are expected to have a substantial impact on the company's future operations and market position.

The market read

The announcement details strategic restructuring, acquisitions, and positive financial performance with revenue growth, indicating a positive outlook for the company.

QMS Medical Allied Services Limited has released an investor presentation detailing its performance for the second quarter and first half of fiscal year 2027. The presentation highlights significant strategic developments, including a composite scheme of arrangement approved on September 25, 2026, to demerge services businesses of QMS and Health Care At Home India Pvt. Ltd. (HCAH) into a separate listed entity. This scheme involves the merger of PSP businesses into Saarathi Healthcare via an all-share swap, with 1.32 crore shares to be issued to HCAH shareholders. The QMS Product business will remain in the currently listed entity.

The company aims to build India's largest Patient Support Program (PSP) platform, targeting a revenue of approximately ₹180 crore for the combined entity (QMS services, Saarthi, and HCAH PSP Division) in FY27, with a total addressable market size of ₹10,000–12,000 crore. QMS is also expanding into diagnostic technology through a binding MOU to acquire 100% of BeamOptics Scientific, integrating R&D and manufacturing capabilities with its distribution network.

Financial highlights for Q2 FY27 show a Net Revenue from Operations of ₹52.5 crore, an 18% increase year-on-year, and for H1 FY27, revenue stood at ₹109.4 crore, a 20% increase. EBITDA for H1 FY27 was ₹14.8 crore, up 11% year-on-year. The company's vision is to revolutionize healthcare by providing comprehensive, technology-driven solutions, leveraging its 30+ years of industry experience and a pan-India network.

Mahesh Makhija, Founder, Chairman and Managing Director, stated that the realignment creates India’s largest pure-play PSP platform, poised for growth. The integration of HCAH's strengths with QMS's relationships and diagnostic capabilities, along with the BeamOptics acquisition, is expected to drive margin expansion and market leadership.

Filing to action

What to do with a filing like this

QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under other investor communications. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.

View original filing